Stocks to Watch This Week: February 2026 Watchlist

The first week of February 2026 brings a wave of market-moving catalysts that could define trading opportunities for weeks to come. Stocks to watch this week include tech heavyweights reporting earnings, biotech names awaiting FDA decisions, and growth compounders showing technical strength. This watchlist breaks down the key names across earnings plays, technical setups, and catalyst-driven opportunities.

Key Takeaways

• Highly anticipated earnings from Google and Amazon headline the busiest week of the reporting period, with major reports scheduled Monday through Thursday.
• Palantir Technologies reports Q4 2025 earnings after close on February 2, with the options market bracing for a 10.47% swing.
• Ascendis Pharma faces an FDA decision on TransCon CNP by February 28, 2026, a potential first-in-class therapy for achondroplasia.
• AMD is expected to report a 20% expansion in earnings from the year-earlier period, with analysts projecting upside potential.

---

Like these picks? Our premium members get our actual portfolio holdings, entry prices, and real-time portfolio update alerts before anyone else. See Premium →

Earnings Plays

Palantir Technologies (PLTR)

Reports: Monday, February 2, After Close

Palantir Technologies will release results for its fourth quarter and fiscal year ended December 31, 2025 on Monday, February 2, 2026, following the close of U.S. markets.

During its Q3 2025 earnings report, Palantir guided Q4 2025 revenue to between $1.327 billion and $1.331 billion, representing 61% YoY growth. CEO Alex Karp highlighted the company's Rule of 40 score of 114%, with year-on-year growth in the US business surging to 77% and US commercial climbing to 121%.

Quick Take: Palantir shares closed out 2025 with a stunning 135% gain, ending the year at $177.75, far outpacing the Nasdaq 100's more modest 21% return. The stock is priced for perfection, and any guidance disappointment could trigger significant volatility.

Advanced Micro Devices (AMD)

Reports: Tuesday, February 3, After Close

AMD's next earnings date is confirmed for Tuesday, February 3, 2026, after market.

The market is looking for AMD to meet or beat the consensus of $9.67 billion in revenue and $1.33 per share. AMD trades at a forward P/E ratio of 124.63, a multiple that embeds significant growth expectations.

Piper Sandler's Harsh Kumar hiked his price target on the stock to $300 last week, signaling a gain of 27% from Friday's close, stating "we believe AMD will deliver revenue upside to the tune of $200 million."

Quick Take: The upgrade is driven by AMD's systems-led strategy, Helios platform, expected margin expansion, and likely double-beat quarter, with strong catalysts not yet fully reflected in consensus.

Alphabet (GOOGL)

Reports: Wednesday, February 4, After Close

Alphabet will hold its quarterly conference call to discuss fourth quarter and fiscal year 2025 financial results on Wednesday, February 4, at 1:30pm Pacific Time.

During Alphabet's third quarter 2025 earnings call, the company reported a milestone $102.3 billion in revenue, marking a 16% year-over-year increase, with significant contributors including a 15% growth in Google Search and a similar increase in YouTube advertising revenues.

The company highlighted its expanding AI capabilities, with the Gemini app now boasting over 650 million monthly active users. Google Cloud also saw robust demand, with its backlog growing 46% quarter-over-quarter to $155 billion.

Quick Take: Analysts are projecting an EPS of $2.62 for the upcoming quarter. AI monetization progress and cloud growth will be key focus areas.

Arm Holdings (ARM)

Reports: Wednesday, February 4, After Close

Arm Holdings will report financial results for the third quarter of fiscal year 2026 on Wednesday, February 4, 2026, after market close.

During the Arm Second Quarter Fiscal Year 2026 earnings call, the company reported revenue reaching $1.14 billion, a 34% increase year-over-year, marking their third consecutive billion-dollar quarter. Royalty revenue hit a record $620 million, up 21% year-over-year.

Quick Take: Arm Holdings is experiencing significant momentum with its record quarter driven by AI chip demand. A strategic partnership with Meta and strong growth projections bolster its expansion narrative in the AI sector.

Roblox (RBLX)

Reports: Thursday, February 5, After Close

Roblox is scheduled to report earnings on February 5, 2026, after close.

In Roblox's Third Quarter 2025 earnings call, the company reported its platform now accounts for 3.2% of global gaming bookings, up from 2.3% the previous year. DAUs increased by 70% year-on-year to 151.5 million. Revenue for Q3 was $1.36 billion, an increase of 48% year-on-year, while bookings rose by 70% to $1.92 billion.

Quick Take: Roblox Q3 2025 revenue hit $1.92B with monthly unique payers increasing 88% to 35.8M. APAC markets showed exceptional growth with Indonesia up 804%. Watch for guidance on 2026 margin trajectory.

---

Catalyst Plays

Ascendis Pharma (ASND)

FDA Decision: February 28, 2026

Ascendis Pharma announced that the FDA notified the company that information submitted on November 5, 2025 constituted a major amendment to the NDA. Accordingly, the FDA has extended the PDUFA target action date by three months to February 28, 2026.

TransCon CNP is a therapy aimed at treating children with achondroplasia, a genetic form of dwarfism. Key metrics include YORVIPATH 2025 revenue of approximately €477M, SKYTROFA 2025 revenue of approximately €206M, total revenue of approximately €720M, and gross margin of approximately 87%.

Quick Take: The TransCon CNP PDUFA extension introduces timing uncertainty for a high-profile catalyst, but does not yet change the core story that execution on current launches and pipeline approvals will be central to near-term sentiment.

Eli Lilly (LLY)

Earnings: February 11, 2026 | Multiple Catalysts

Eli Lilly is scheduled to report earnings on February 11, 2026, before open.

Orforglipron has been the recipient of a new FDA voucher that allows for much shorter approval times, between one and two months. So, orforglipron could earn regulatory approvals early next year, hopefully in the first quarter.

The company is also expecting readouts from seven additional phase 3 trials in 2026 evaluating retatrutide in obesity and type 2 diabetes. With Morgan Stanley analysts estimating the global weight-loss medication market to be worth $150 billion by 2035, a differentiated drug like retatrutide could capture a significant share.

Quick Take: During Eli Lilly's Q3 2025 earnings call, the company reported a 54% increase in revenue compared to the same period last year. Lilly gained substantial market share in the incretin analogs market, accounting for nearly 60% of prescriptions in the U.S.

---

Technical Setup

UiPath (PATH)

Agentic AI Breakout Candidate

UiPath is at the center of a theme that could become a leading theme this year: agentic AI. The company describes its mission as shaping the future of agentic automation. The UiPath Platform brings together AI agents, robots, people, and machine learning models to collaborate across an organization.

From a technical perspective, there's firm momentum behind the stock. PATH has been forming a bullish base with higher lows and higher highs in recent months. For a major breakout to be confirmed, the stock would first need to clear resistance at $18, followed by its 52-week high near $20.

Quick Take: Technically, the stock just broke out of a lengthy consolidation, setting up a potential bull run. If the breakout level of $20 can hold and the stock consolidates at higher levels, this is one agentic AI stock that could surprise many this year.

---

Weekly Earnings Calendar Summary

---

Options Activity to Monitor

Palantir Technologies Q4 earnings are on deck with the options market bracing for a 10.47% swing. This elevated implied volatility creates opportunities for both directional and premium-selling strategies.

For AMD, traders are using Iron Condor and Calendar Spreads for neutral bets or Straddles and Strangles for directional plays, targeting 9.75% volatility swings.

---

The Bottom Line

This week's earnings parade offers multiple entry points for growth-focused investors. The AI theme continues to dominate, with PLTR, AMD, GOOGL, and ARM all reporting within days of each other. For biotech exposure, ASND presents a binary FDA catalyst later this month.

The outlook for 2026 is bullish, supported by a disciplined approach to the U.S. economy and equities. For a third consecutive year, stocks stateside are expected to experience a broadening of the powerful rally that began in late 2022.

Position sizing remains critical given the elevated volatility around earnings. Consider scaling into positions rather than taking full-sized bets ahead of these binary events.

---

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor before making investment decisions.